Dose-Effect Relationship of Alkylating Agents on Testicular Function in Male Survivors of Childhood Lymphoma

Pediatric Hematology and Oncology

Volumn 32, Issue 8, 2015, Pages 613-623

  Servitzoglou, Marina ^a   De Vathaire, Florent ^b   Oberlin, Odile ^a   Patte, Catherine ^a   Thomas Teinturier, Cécile ^b,c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

alkylating agents; childhood lymphoma; fertility; testicular function

Indexed keywords

ALKYLATING AGENT; ASPARAGINASE; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FOLLITROPIN; LOMUSTINE; LUTEINIZING HORMONE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; TIOGUANINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

ADOLESCENT; ARTICLE; AZOOSPERMIA; B CELL LYMPHOMA; B CELL NONHODGKIN LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVOR; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOLLITROPIN BLOOD LEVEL; HODGKIN DISEASE; HUMAN; INFERTILITY; LARGE CELL LYMPHOMA; LUTEINIZING HORMONE BLOOD LEVEL; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; OLIGOSPERMIA; PUBERTY; SCHOOL CHILD; SIDE EFFECT; T CELL NONHODGKIN LYMPHOMA; TESTIS FUNCTION; TREND STUDY; ADULT; BLOOD; FOLLOW UP; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMA, T-CELL; METABOLISM; SURVIVOR; TESTIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; LUTEINIZING HORMONE; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMA, T-CELL; MALE; SURVIVORS; TESTIS;

EID: 84951570227     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2015.1085933     Document Type: Article

References (44)

1. BrydøyM, Fossa S, Dahl O, Bjoro T. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol. 2007;46:480-489.
2. Wasilewski-Masker K, Seidel KD, LeisenringW, et al.Male infertility in long-termsurvivors of pediatric cancer: A report fromthe Childhood Cancer Survivor Study. J Cancer Surviv. 2014;8:437-447.
3. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917-2931.
4. Kenney LB, Cohen LE, Shnorhavorian M, et al. Male reproductive health after childhood, adolescent, and young adult cancers: A report from the Children's Oncology Group. J Clin Oncol. 2012;30:3408-3416.
5. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol. 2005;6:209-218.
6. Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer Survivor Study: A National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol. 2009;27:2308-2318.
7. Green DM, Liu W, Kutteh WH, et al. Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study. Lancet Oncol. 2014;15:1215-1223.
8. Rueffer U, Breuer K, Josting A, et al. Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol. 2001;12:1307-1311.
9. Blumenfeld Z, Dann E, Avivi I, EpelbaumR, Rowe JM. Fertility after treatment forHodgkin's disease. Ann Oncol. 2002;13(Suppl 1):138-147.
10. vanDorpW, van Beek RD, Laven JSE, et al. Long-termendocrine side effects of childhoodHodgkin's lymphoma treatment: A review. Hum Reprod Update. 2012;18:12-18.
11. Schrader M, Heicappell R, Müller M, Straub B, Miller K. Impact of chemotherapy on male fertility. Onkologie. 2001;24:326-330.
12. Lähteenmäki PM, ArolaM, Suominen J, et al.Male reproductive health after childhood cancer. Acta Paediatr. 2008;97:935-942.
13. Kumanov P, Nandipati K, Tomova A, et al. Inhibin B is a better marker of spermatogenesis than other hormones in the evaluation of male factor infertility. Fertil Steril. 2006;86: 332-338.
14. Green DM, Zhu L, Zhang N, et al. Lack of specificity of plasma concentrations of inhibin B and follicle-stimulating hormone for identification of azoospermic survivors of childhood cancer: A report fromthe St Jude lifetime cohort study. J Clin Oncol. 2013;31:1324-1328.
15. Donaldson SS, Link MP. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol. 1987;5:742-749.
16. Bonadonna G, Santoro A. ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev. 1982;9:21-35.
17. Weiner MA, Leventhal BG, Marcus R, et al. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stageHodgkin's disease in pediatric patients: A PediatricOncologyGroup study. J Clin Oncol. 1991;9:1591-1598.
18. Dörffel W, Lüders H, Rühl U, et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr. 2003;215:139-145.
19. Nachman JB, Sposto R, Herzog P, et al., Children's Cancer Group. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20:3765-3771.
20. Patte C, Auperin A, Michon J, et al., Société Française d'Oncologie Pédiatrique. The Société Francaise d'Oncologie Peédiatrique LMB89 protocol: highly effectivemultiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97:3370-3379.
21. Patte C, Kalifa C, Flamant F, et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992;20:105-113.
22. Jabbour E, Koscienly S, Sebban C, et al.High survival ratewith the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia. 2006;20:814-819.
23. Vannier JP, Patte C, Philip T, et al. Treatment of extensive B-cell lymphoma in children: studies of the French Pediatric Oncology Society. Bull Cancer. 1988;75:61-68.
24. Patte C, Michon J, Frappaz D, Leverger G.Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults. Baillieres Clin Haematol. 1994;7:339-348.
25. Cairo MS, Sposto R, GerrardM, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30:387-393.
26. Schellong G, Brämswig JH, Schwarze EW,WannenmacherM. An approach to reduce treatment and invasive staging in childhoodHodgkin's disease: The sequence of theGerman DALmulticenter studies. Bull Cancer. 1988;75:41-51.
27. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol. 2000;18:1500-1507.
28. Le Deley M, Rosolen A, Williams D, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: Results of the randomized ALCL99-Vinblastine trial. J Clin Oncol. 2010;28:3987-3993.
29. Brugieres L, Le Deley M, Pacquement H, et al. CD30 Anaplastic large-cell lymphoma in children: Analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92;3591-3598.
30. Viviani S, Santoro A, Ragni G, et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease: comparative results ofMOPP and ABVD. Eur J Clin Oncol. 1985;21:601-606.
31. van der KaaijM,Heutte N, Le StangN, et al.Gonadal function inmales after chemotherapy for earlystage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment ofCancer:EORTCLymphomaGroup and the Groupe d'étude des Lymphomes de l'Adulte. J Clin Oncol. 2007;25:2825-2832.
32. Ben Arush MW, Solt I, Lightman A, et al. Male gonadal function in survivors of childhood Hodgkin and non-Hodgkin lymphoma. Pediatr Hematol Oncol. 2000;17:239-245.
33. Hobbie WL, Ginsberg JP, Ogle SK, et al. Fertility in males treated for Hodgkin's disease with COPP/ABVD hybrid. Pediatr Blood Cancer. 2005;44:193-196.
34. Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr. 2005;34:12-17.
35. Dohle G.Male infertility in cancer patients: review of the literature. Int J Urol. 2010;17:327-331.
36. Green DM, Liu W, Kutteh WH, et al. Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study. Lancet Oncol. 2014;15:1215-1223.
37. van den Berg H, Furstner F, van den Bos C, Behrendt H. Decreasing the Number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease. Pediatr Blood Cancer. 2004;42:210-215.
38. Mauz-Cörholz C, Hasenclever D, Dörffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standardOPPA-COPP in girls have comparable effectiveness in pediatricHodgkin's lymphoma: The GPOH-HD-2002 study. J Clin Oncol. 2010;28:3680-3686.
39. van Casteren N, van der Linden G, Hakvoort-Cammel F, et al. Effect of childhood cancer treatment on fertilitymarkers in adultmale long-termsurvivors. Pediatr Blood Cancer. 2009;52:108-112.
40. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773-2780.
41. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of PediatricOncology study MDH90. JClin Oncol. 2000;18:1500-1507.
42. Jaffe N, Sullivan MP, Ried H, et al. Male reproductive function in long-term survivors of childhood cancer. Med Pediatr Oncol. 1988;16:241-247.
43. Howell S, Shalet S. Gonadal damage fromchemotherapy and radiotherapy. Endocrinol Metabol Clin North Am. 1998;27:927-943.
44. Sieniawski M, Reineke T, Josting A, et al. Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol. 2008;19:1795-1801.